|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||








* Transplantation Research Center, Brigham and Womens Hospital and Childrens Hospital Boston, Harvard Medical School, and
Immunology Research Division, Department of Pathology, Brigham and Womens Hospital and Harvard Medical School, Boston, MA 02115;
Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114;
Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan;
¶
Section of Nephrology (Department of Medicine) and Section of Immunobiology, Yale University School of Medicine, New Haven, CT 06520; and
||
Renal Section, Division of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom
The inability to reproducibly induce robust and durable transplant tolerance using CD28-B7 pathway blockade is in part related to the persistence of alloreactive effector/memory CD8+ T cells that are less dependent on this pathway for their cellular activation. We studied the role of the novel T cell costimulatory pathway, CD27-CD70, in alloimmunity in the presence and absence of CD28-B7 signaling. CD70 blockade prolonged survival of fully mismatched vascularized cardiac allografts in wild-type murine recipients, and in CD28-deficient mice induced long-term survival while significantly preventing the development of chronic allograft vasculopathy. CD70 blockade had little effect on CD4+ T cell function but prevented CD8+ T cell-mediated rejection, inhibited the proliferation and activation of effector CD8+ T cells, and diminished the expansion of effector and memory CD8+ T cells in vivo. Thus, the CD27-CD70 pathway is critical for CD28-independent effector/memory CD8+ alloreactive T cell activation in vivo. These novel findings have important implications for the development of transplantation tolerance-inducing strategies in primates and humans, in which CD8+ T cell depletion is currently mandatory.
This article has been cited by other articles:
![]() |
M. Manocha, R. Svend, A. Laouar, G. Liao, A. Bhan, J. Borst, C. Terhorst, and N. Manjunath Blocking CD27-CD70 Costimulatory Pathway Suppresses Experimental Colitis J. Immunol., July 1, 2009; 183(1): 270 - 276. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hashimoto-Okada, T. Kitawaki, N. Kadowaki, S. Iwata, C. Morimoto, T. Hori, and T. Uchiyama The CD70-CD27 interaction during the stimulation with dendritic cells promotes naive CD4+ T cells to develop into T cells producing a broad array of immunostimulatory cytokines in humans Int. Immunol., June 25, 2009; (2009) dxp056v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Keller, Y. Xiao, V. Peperzak, S. H. Naik, and J. Borst Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting Blood, May 21, 2009; 113(21): 5167 - 5175. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kraetzel, B. Stoelcker, G. Eissner, G. Multhoff, M. Pfeifer, E. Holler, and C. Schulz NKG2D-dependent effector function of bronchial epithelium-activated alloreactive T-cells Eur. Respir. J., September 1, 2008; 32(3): 563 - 570. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xiao, V. Peperzak, A. M. Keller, and J. Borst CD27 Instructs CD4+ T Cells to Provide Help for the Memory CD8+ T Cell Response after Protein Immunization J. Immunol., July 15, 2008; 181(2): 1071 - 1082. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Ford, M. E. Wagener, S. S. Hanna, T. C. Pearson, A. D. Kirk, and C. P. Larsen A Critical Precursor Frequency of Donor-Reactive CD4+ T Cell Help Is Required for CD8+ T Cell-Mediated CD28/CD154-Independent Rejection J. Immunol., June 1, 2008; 180(11): 7203 - 7211. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Reich-Zeliger, E. Bachar-Lustig, A. Bar-Ilan, and Y. Reisner Tolerance Induction in Presensitized Bone Marrow Recipients by Veto CTLs: Effective Deletion of Host Anti-Donor Memory Effector Cells J. Immunol., November 15, 2007; 179(10): 6389 - 6394. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Valujskikh and X. C. Li Frontiers in Nephrology: T Cell Memory as a Barrier to Transplant Tolerance J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2252 - 2261. [Full Text] [PDF] |
||||
![]() |
J. N. Beilke and R. G. Gill Frontiers in Nephrology: The Varied Faces of Natural Killer Cells in Transplantation Contributions to Both Allograft Immunity and Tolerance J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2262 - 2267. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Soares, H. Waechter, N. Glaichenhaus, E. Mougneau, H. Yagita, O. Mizenina, D. Dudziak, M. C. Nussenzweig, and R. M. Steinman A subset of dendritic cells induces CD4+ T cells to produce IFN-{gamma} by an IL-12-independent but CD70-dependent mechanism in vivo J. Exp. Med., May 14, 2007; 204(5): 1095 - 1106. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Salama, K. L. Womer, and M. H. Sayegh Clinical Transplantation Tolerance: Many Rivers to Cross J. Immunol., May 1, 2007; 178(9): 5419 - 5423. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Sanchez, J. A. McWilliams, C. Haluszczak, H. Yagita, and R. M. Kedl Combined TLR/CD40 Stimulation Mediates Potent Cellular Immunity by Regulating Dendritic Cell Expression of CD70 In Vivo J. Immunol., February 1, 2007; 178(3): 1564 - 1572. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. McEarchern, E. Oflazoglu, L. Francisco, C. F. McDonagh, K. A. Gordon, I. Stone, K. Klussman, E. Turcott, N. van Rooijen, P. Carter, et al. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities Blood, February 1, 2007; 109(3): 1185 - 1192. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Y. Taraban, T. F. Rowley, D. F. Tough, and A. Al-Shamkhani Requirement for CD70 in CD4+ Th Cell-Dependent and Innate Receptor-Mediated CD8+ T Cell Priming. J. Immunol., September 1, 2006; 177(5): 2969 - 2975. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-L. Law, K. A. Gordon, B. E. Toki, A. K. Yamane, M. A. Hering, C. G. Cerveny, J. M. Petroziello, M. C. Ryan, L. Smith, R. Simon, et al. Lymphocyte Activation Antigen CD70 Expressed by Renal Cell Carcinoma Is a Potential Therapeutic Target for Anti-CD70 Antibody-Drug Conjugates Cancer Res., February 15, 2006; 66(4): 2328 - 2337. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Kemball, E. D. H. Lee, E. Szomolanyi-Tsuda, T. C. Pearson, C. P. Larsen, and A. E. Lukacher Costimulation Requirements for Antiviral CD8+ T Cells Differ for Acute and Persistent Phases of Polyoma Virus Infection J. Immunol., February 1, 2006; 176(3): 1814 - 1824. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. F. Israel, M. Gulley, S. Elmore, S. Ferrini, W.-h. Feng, and S. C. Kenney Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas Mol. Cancer Ther., December 1, 2005; 4(12): 2037 - 2044. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ito, T. Ueno, M. R. Clarkson, X. Yuan, M. M. Jurewicz, H. Yagita, M. Azuma, A. H. Sharpe, H. Auchincloss Jr, M. H. Sayegh, et al. Analysis of the Role of Negative T Cell Costimulatory Pathways in CD4 and CD8 T Cell-Mediated Alloimmune Responses In Vivo J. Immunol., June 1, 2005; 174(11): 6648 - 6656. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |